213 related articles for article (PubMed ID: 32319038)
1. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.
Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM
Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.
Zhou Z; Fan Y; Thomason D; Tang W; Liu X; Zhou ZY; Macaulay D; Fischer A
Adv Ther; 2019 May; 36(5):1100-1113. PubMed ID: 30929184
[TBL] [Abstract][Full Text] [Related]
3. The clinical and economic burden of systemic sclerosis related interstitial lung disease.
Morrisroe K; Stevens W; Sahhar J; Ngian GS; Ferdowsi N; Hansen D; Patel S; Hill CL; Roddy J; Walker J; Proudman S; Nikpour M
Rheumatology (Oxford); 2020 Aug; 59(8):1878-1888. PubMed ID: 31740961
[TBL] [Abstract][Full Text] [Related]
4. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
[TBL] [Abstract][Full Text] [Related]
5. Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population-based cohort study.
Knarborg M; Løkke A; Hilberg O; Ibsen R; Sikjaer MG
Respirology; 2022 May; 27(5):341-349. PubMed ID: 35224821
[TBL] [Abstract][Full Text] [Related]
6. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
7. Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study.
Davidsen JR; Miedema J; Wuyts W; Kilpeläinen M; Papiris S; Manali E; Robalo Cordeiro C; Morais A; Pérez M; Asijee G; Cendoya D; Soulard S
Adv Ther; 2021 Jan; 38(1):521-540. PubMed ID: 33156462
[TBL] [Abstract][Full Text] [Related]
8. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
Nasser M; Larrieu S; Boussel L; Si-Mohamed S; Bazin F; Marque S; Massol J; Thivolet-Bejui F; Chalabreysse L; Maucort-Boulch D; Hachulla E; Jouneau S; Le Lay K; Cottin V
Respir Res; 2021 May; 22(1):162. PubMed ID: 34030695
[TBL] [Abstract][Full Text] [Related]
9. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States.
Fan Y; Bender S; Shi W; Zoz D
J Manag Care Spec Pharm; 2020 Dec; 26(12):1539-1547. PubMed ID: 32996805
[TBL] [Abstract][Full Text] [Related]
10. Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease.
Løkke A; Castello L; Pinheiro Martins P; Soulard S; Hilberg O
Adv Ther; 2023 Dec; 40(12):5502-5518. PubMed ID: 37837527
[TBL] [Abstract][Full Text] [Related]
11. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States.
Zhou Z; Fan Y; Tang W; Liu X; Thomason D; Zhou ZY; Macaulay D; Fischer A
J Rheumatol; 2019 Aug; 46(8):920-927. PubMed ID: 30770505
[TBL] [Abstract][Full Text] [Related]
13. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
[TBL] [Abstract][Full Text] [Related]
14. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population.
Furst DE; Fernandes AW; Iorga SR; Greth W; Bancroft T
J Rheumatol; 2012 Dec; 39(12):2303-9. PubMed ID: 23027885
[TBL] [Abstract][Full Text] [Related]
15. Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.
Kuwana M; Saito A; Sakamoto W; Raabe C; Saito K
Adv Ther; 2022 May; 39(5):2222-2235. PubMed ID: 35316503
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis.
Qiu M; Nian X; Pang L; Yu P; Zou S
Int J Rheum Dis; 2021 Dec; 24(12):1449-1459. PubMed ID: 34418313
[TBL] [Abstract][Full Text] [Related]
17. Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years.
Pope JE; Quansah K; Hassan S; Seung SJ; Flavin J; Kolb M
J Rheumatol; 2021 Sep; 48(9):1427-1434. PubMed ID: 33795325
[TBL] [Abstract][Full Text] [Related]
18. High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis.
Tomiyama F; Watanabe R; Ishii T; Kamogawa Y; Fujita Y; Shirota Y; Sugimura K; Fujii H; Harigae H
Tohoku J Exp Med; 2016 Aug; 239(4):297-305. PubMed ID: 27487743
[TBL] [Abstract][Full Text] [Related]
19. Interstitial lung disease in South Africans with systemic sclerosis.
Ashmore P; Tikly M; Wong M; Ickinger C
Rheumatol Int; 2018 Apr; 38(4):657-662. PubMed ID: 29185086
[TBL] [Abstract][Full Text] [Related]
20. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
